Tag: MONOGRAPH

  • 17-alpha-Estradiol

    Plain-language summaryIntrigue 75 / 100

    17-alpha-Estradiol is the mirror-image isomer of regular estradiol, identical except for the orientation of one hydroxyl group. That single difference makes it bind classical estrogen receptors about 100 times more weakly, eliminating most of the feminizing effects. The reason it appears in longevity literature: the NIA Interventions Testing Program (a multi-laboratory rodent screening program designed to spot real lifespan-extending drugs) reproducibly showed that 17-alpha-estradiol extends male mouse lifespan by about 12 percent, with no effect in females. The mechanism is incompletely understood, possibly involving non-classical estrogen receptors or hypothalamic effects. One of a handful of compounds with replicated ITP data, but no human trials. Genuinely intriguing sleeper. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Non-feminizing endogenous estradiol stereoisomer with 5-alpha-reductase inhibitory activity and lifespan-extending properties

    A naturally occurring 17-alpha-epimer of estradiol with approximately 100-fold reduced classical estrogen receptor affinity, topical registration as alfatradiol for androgenetic alopecia, and reproducible male-specific lifespan extension in the NIA Interventions Testing Program, mediated through estrogen receptor alpha signaling in the hypothalamus and liver.

    Abstract

    17-alpha-Estradiol (estra-1,3,5(10)-triene-3,17-alpha-diol; CAS 57-91-0; alfatradiol; molecular formula C18H24O2; molecular weight 272.39 g/mol) is the 17-alpha-stereoisomer of the principal mammalian estrogen 17-beta-estradiol, distinguished solely by the axial (alpha) orientation of the hydroxyl group at carbon 17 of the steroid D-ring. The compound occurs endogenously at low concentrations in mammalian brain and peripheral tissues and has been characterized since the 1950s as a weak estrogen with approximately 100-fold lower binding affinity for the classical nuclear estrogen receptors ER-alpha and ER-beta relative to the 17-beta-epimer [1, 2]. Despite this reduced receptor engagement, 17-alpha-estradiol retains potent estrogen receptor-independent antioxidant activity equivalent to 17-beta-estradiol in lipid peroxidation assays and neuroprotection models [3, 4], inhibits 5-alpha-reductase and aromatase in skin and hair follicle tissue (the basis for its topical registration as alfatradiol in several European jurisdictions for androgenetic alopecia) [5, 6], and has emerged as one of the most robustly validated lifespan-extending compounds in the National Institute on Aging Interventions Testing Program (ITP), a rigorous, multi-site, genetically heterogeneous mouse longevity screening platform.

    The ITP demonstrated that dietary 17-alpha-estradiol at 14.4 parts per million (approximately 2 mg/kg/day mouse-equivalent) extended median lifespan by approximately 19 percent in male UM-HET3 mice when initiated at 16 months of age and by approximately 11 percent when initiated at 20 months, with no lifespan extension observed in female mice at any initiation age [7, 8, 9]. The male specificity of the lifespan effect has been replicated across three independent ITP sites (the Jackson Laboratory, the University of Michigan, and the University of Texas Health Science Center) and is among the largest and most reproducible lifespan extensions reported in the ITP, comparable in magnitude to acarbose and exceeded only by rapamycin. The sex-specific pattern has driven substantial mechanistic investigation. Stout et al. (2017) demonstrated that 17-alpha-estradiol alleviates age-related metabolic and inflammatory dysfunction in male mice without inducing feminization, with treated males showing reduced fasting glucose, reduced fasting insulin, reduced glycosylated hemoglobin, reduced visceral adiposity, reduced circulating and adipose tissue pro-inflammatory cytokines, and increased AMP-activated protein kinase activity in visceral adipose tissue [10]. Steyn et al. (2018) established that 17-alpha-estradiol acts through hypothalamic pro-opiomelanocortin (POMC) expressing neurons to reduce feeding behavior, with near-complete loss of the anorectic response in POMC-neuron-ablated mice [11]. Mann et al. (2020) demonstrated through liver-specific and global ER-alpha knockout models that the metabolic health benefits of 17-alpha-estradiol (reductions in fasting insulin, HbA1c, glucose intolerance, and visceral adiposity) are mediated through estrogen receptor alpha, resolving prior uncertainty about whether a non-classical receptor was responsible [12]. Garratt et al. (2017, 2018) reported that males, but not females, metabolize 17-alpha-estradiol into one or more estriol derivatives, and that the sex-specific beneficial effects may depend on a downstream metabolite rather than on the parent compound [13, 14].

    The compound has limited human clinical data. A Phase I safety study in eight healthy postmenopausal women demonstrated tolerability of single rising oral doses (50, 100, and 200 micrograms) with no adverse events, no detectable conversion to 17-beta-estradiol, and no feminizing effects [15]. Topical formulations (alfatradiol 0.025 percent solution, marketed as Ell-Cranell alpha) are registered in Germany, Austria, and several other European jurisdictions for androgenetic alopecia in men and women, with demonstrated stabilization of hair loss through local 5-alpha-reductase inhibition and aromatase induction [5, 6]. No clinical trials of oral 17-alpha-estradiol for longevity, metabolic, or neuroprotective endpoints have been completed or registered in humans as of the monograph revision date.

    This monograph reviews the chemistry, stereochemistry, and synthesis of 17-alpha-estradiol; the molecular pharmacology across classical estrogen receptors, non-classical signaling pathways, 5-alpha-reductase inhibition, and antioxidant mechanisms; pharmacokinetics in rodent and limited human contexts; the preclinical evidence base from the ITP and mechanistic studies; the clinical evidence from the Phase I oral safety study and topical alopecia registration; sourcing and quality verification; reconstitution and handling; stack interactions; adverse events and safety signals; and a comparative assessment of five alternative longevity or non-feminizing estrogen candidates against 17-alpha-estradiol on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1475Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Palmitoylethanolamide

    Plain-language summaryIntrigue 64 / 100

    Palmitoylethanolamide (PEA) is a fatty acid amide your body makes from membrane lipids, first identified in egg yolk in 1957 because of its anti-inflammatory effects. It does not bind cannabinoid receptors directly. Instead it activates the PPAR-alpha nuclear receptor, stabilizes mast cells (the immune cells that release histamine), and competes with anandamide for the FAAH enzyme, indirectly raising endocannabinoid tone. Decades of European clinical work, particularly in Italy, support its use for chronic pain, neuropathy, and sciatica, with a generally clean safety record and meaningful effect sizes. It is sold as a supplement in the US and as a registered medical food in parts of Europe. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Endogenous N-acylethanolamide lipid mediator with peroxisome proliferator-activated receptor alpha agonism and mast cell modulatory activity

    An endogenous fatty acid amide biosynthesized from membrane phospholipids, identified as an anti-inflammatory factor in the 1950s and subsequently characterized as a peroxisome proliferator-activated receptor alpha agonist with broad analgesic, anti-inflammatory, neuroprotective, and mast cell stabilizing activity across chronic pain, neuroinflammation, and neurodegenerative disease models.

    Abstract

    Palmitoylethanolamide (PEA; CAS 544-31-0; molecular formula C18H37NO2; molecular weight 299.49 g/mol) is an endogenous fatty acid amide of the N-acylethanolamide class, biosynthesized on demand from membrane N-palmitoyl-phosphatidylethanolamine by the enzyme N-acyl-phosphatidylethanolamine-selective phospholipase D (NAPE-PLD) and degraded principally by fatty acid amide hydrolase (FAAH) and N-acylethanolamine-hydrolyzing acid amidase (NAAA) to palmitic acid and ethanolamine. The compound was first identified as a crystalline anti-inflammatory factor isolated from soybean lecithin by Kuehl et al. in 1957, following earlier observations by Coburn et al. (1954) that egg yolk protected against experimental anaphylactic arthritis. The Nobel laureate Rita Levi-Montalcini and colleagues subsequently characterized PEA as a modulator of mast cell degranulation and proposed the autacoid local injury antagonism (ALIA) mechanism in 1993, establishing the conceptual framework for PEA as an endogenous resolution factor in inflammation.

    The principal molecular target of PEA is the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR-alpha), at which PEA acts as a direct agonist with an EC50 of approximately 3.1 micromolar in cell-based reporter assays. Lo Verme et al. (2005) demonstrated that the anti-inflammatory actions of PEA in carrageenan-induced paw edema and phorbol ester-induced ear edema models are abolished in PPAR-alpha knockout mice, establishing PPAR-alpha as the principal mediator of PEA anti-inflammatory pharmacology. Additional receptor targets include the orphan G-protein coupled receptors GPR55 and GPR119, the transient receptor potential vanilloid type 1 channel (TRPV1, via indirect potentiation), and a mast cell surface receptor pharmacologically consistent with a peripheral cannabinoid site. PEA does not bind with meaningful affinity to classical cannabinoid receptors CB1 or CB2 but modulates the endocannabinoid system indirectly through an entourage mechanism: competition for FAAH-mediated degradation elevates tissue levels of the endocannabinoid anandamide, thereby potentiating anandamide signaling at CB1, CB2, and TRPV1.

    The clinical evidence base for PEA spans chronic pain, neuropathic pain, neuroinflammation, and neurodegenerative disease. A 2023 systematic review and meta-analysis of double-blind randomized controlled trials (Scuteri et al., Nutrients, 2023) encompassing 12 studies and approximately 1300 patients demonstrated that oral PEA at 300 to 1200 mg daily produces statistically significant and clinically meaningful pain intensity reduction compared to placebo or active control, with effect emerging at 30 days and increasing through 60 days of treatment. Specific indications with positive randomized controlled trial evidence include sciatic pain, diabetic peripheral neuropathy, carpal tunnel syndrome, temporomandibular joint disorder, chronic low back pain, endometriosis-associated pelvic pain, and fibromyalgia. Micronized (mPEA) and ultramicronized (umPEA) particle-size formulations have been developed to overcome the poor aqueous solubility and limited oral bioavailability of native crystalline PEA, with the micronization process increasing the specific surface area and producing substantially improved absorption and tissue distribution.

    PEA exhibits a favorable safety profile consistent with its status as an endogenous compound and a natural component of the human diet (present in egg yolk, soybean lecithin, peanut meal, and other food sources). Across more than 40 clinical studies and approximately 3000 patient-exposures, no serious adverse drug reactions have been attributed to PEA supplementation at doses up to 1200 mg daily for up to 120 days. The compound is marketed as a medical food or dietary supplement in multiple European jurisdictions (Normast, PeaPure, Levagen) and is available as a research-grade preparation from multiple chemical suppliers. PEA is not approved as a drug by the United States Food and Drug Administration or by the European Medicines Agency; its regulatory status varies by jurisdiction between dietary supplement, medical food, and food for special medical purposes.

    This monograph documents the chemistry, biosynthesis, and degradation of PEA; the multi-target molecular pharmacology including PPAR-alpha agonism, GPR55 and GPR119 signaling, mast cell modulation, and entourage potentiation of endocannabinoid tone; the pharmacokinetic profile with emphasis on formulation-dependent bioavailability; the preclinical pharmacology across pain, inflammation, and neurodegeneration models; the clinical evidence base in chronic and neuropathic pain, neuroinflammatory conditions, and neurodegenerative disease; sourcing and quality verification; reconstitution and handling; stack interactions and combinations; adverse events and safety signal; and a comparative assessment of five alternative anti-inflammatory lipid mediators (cannabidiol, oleoylethanolamide, stearoylethanolamide, N-arachidonoylethanolamide, and resolvin E1) against PEA on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1494Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • SkQ1

    Plain-language summaryIntrigue 67 / 100

    SkQ1 (Visomitin) is the Russian answer to MitoQ: a mitochondria-targeted antioxidant that uses a positively charged triphenylphosphonium tail to drag plastoquinone, an antioxidant from plant chloroplasts, deep into the mitochondrial inner membrane where oxidative damage actually happens. The molecule was developed by Vladimir Skulachev, one of the giants of mitochondrial bioenergetics, and his group has produced extensive preclinical data in aging models. It is approved as eye drops in Russia for dry eye disease, with measurable clinical benefit. The lifespan and longevity data come almost entirely from Skulachev’s lab, which is the principal weakness of the file. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Mitochondria-targeted plastoquinone-based antioxidant conjugated to a penetrating lipophilic cation (triphenylphosphonium)

    A rechargeable, mitochondria-accumulating plastoquinone derivative developed at Lomonosov Moscow State University as a direct scavenger of reactive oxygen species at the inner mitochondrial membrane, with preclinical geroprotective, cytoprotective, and anti-inflammatory activity across multiple organ systems and a registered ophthalmic formulation (Visomitin) for dry eye syndrome.

    Abstract

    SkQ1 (10-(6′-plastoquinonyl)decyltriphenylphosphonium), designated a “Skulachev ion” after its principal developer Vladimir P. Skulachev, is a synthetic mitochondria-targeted antioxidant composed of a plastoquinone moiety linked by a ten-carbon aliphatic chain to a triphenylphosphonium cation. The triphenylphosphonium group exploits the large negative-inside mitochondrial membrane potential (approximately 180 millivolts) to drive electrophoretic accumulation of the compound within the mitochondrial matrix at concentrations estimated to reach 10(8)-fold above extracellular levels. Within the inner mitochondrial membrane, the plastoquinone headgroup intercalates near the cardiolipin fatty acid chains and directly quenches peroxyl radicals, with regeneration of the reduced (antioxidant-active) form by Complex I at the IQ site and by Complex III at the Qi site of the electron transport chain. This rechargeable antioxidant cycle distinguishes SkQ1 from stoichiometric scavengers and positions it as a catalytic antioxidant with sustained activity at nanomolar external concentrations. The compound was developed beginning in the early 2000s at the A. N. Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, within a research framework centered on Skulachev’s hypothesis that aging represents a form of programmed organismal death (phenoptosis) mediated by mitochondrial reactive oxygen species (mtROS). Preclinical studies in organisms spanning fungi (Podospora anserina), crustaceans (Ceriodaphnia affinis), insects (Drosophila melanogaster), fish (Nothobranchius furzeri), and mammals (mice and rats) have demonstrated lifespan extension, delay or reversal of age-related pathologies, and suppression of mtROS-driven tissue damage under a variety of experimental conditions. In the senescence-accelerated OXYS rat strain, SkQ1 prevented or reversed cataracts, retinopathy resembling age-related macular degeneration, osteoporosis, and neurodegenerative phenotypes resembling Alzheimer’s disease. In outbred and inbred mouse strains, SkQ1 extended median and maximum lifespan under non-specific-pathogen-free housing conditions, with effect sizes dependent on ambient pathogen exposure. The compound prevented rapid death caused by mechanistically diverse acute shocks including bacterial lipopolysaccharide, intravenous mitochondrial injection, cold exposure, and toxic insult. The ophthalmic formulation of SkQ1 (Visomitin, 0.155 micrograms per milliliter ophthalmic solution) was approved by the Russian Ministry of Health in December 2011 for the treatment of dry eye syndrome and early cataracts. In the United States, Mitotech S.A. advanced SkQ1 ophthalmic solution through a positive Phase 2 clinical trial demonstrating statistically significant improvement in corneal fluorescein staining and lissamine green staining relative to placebo in 91 subjects with mild to moderate dry eye disease. Two subsequent Phase 3 studies (VISTA-1, 452 subjects; VISTA-2, 610 subjects) did not meet their co-primary endpoints, although VISTA-2 demonstrated statistically significant superiority in a pre-specified secondary endpoint of central corneal fluorescein staining change in a Schirmer’s score-defined subpopulation. Phase 1 oral formulation studies were conducted in Russia in 2016. Preclinical pharmacology extends beyond ophthalmology to include cardioprotection (hemorrhagic shock, doxorubicin-induced cardiomyopathy), nephroprotection (cisplatin-induced and ischemia-reperfusion acute kidney injury with ferroptosis inhibition), neuroprotection (stroke, Alzheimer’s disease models in OXYS rats), hepatoprotection, suppression of experimental colitis and autoimmune arthritis, wound healing acceleration, tumor growth inhibition in fibrosarcoma and rhabdomyosarcoma models, and antibacterial activity at micromolar concentrations. Safety pharmacology in rats and dogs has demonstrated a wide therapeutic window with no adverse effects on the central nervous system, cardiovascular system, or respiratory system at doses orders of magnitude above the efficacious range. The compound does not induce hepatic cytochrome P450 enzymes. This monograph reviews the chemistry, structural pharmacology, and rechargeable antioxidant mechanism of SkQ1; the comprehensive preclinical evidence across geroprotective, cytoprotective, and anti-inflammatory applications; the clinical evidence base in dry eye disease; the pharmacokinetic characteristics; sourcing and quality considerations; reconstitution and handling protocols; stack-interaction implications; the adverse-event and safety profile; and a structured comparative assessment of five mitochondria-targeted antioxidant candidates against SkQ1 on five competency standards (novelty, effect size, promising potential, side-effect profile, and overall validation).

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1467Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Fluvoxamine

    Plain-language summaryIntrigue 71 / 100

    Fluvoxamine (Luvox) is an SSRI with a structural backbone unlike the others in its class, developed by Solvay and approved in the US in 1994. It is a first-line drug for OCD and also useful in social anxiety. The pharmacological wrinkle that makes researchers care about it is high-affinity activation of the sigma-1 receptor, an unusual cellular target involved in stress response, neuroprotection, and possibly viral defense. That sigma-1 hook briefly made fluvoxamine a topic of pandemic-era research after small trials suggested it might reduce hospitalization risk in early COVID-19, although larger follow-up trials have been mixed. It also strongly blocks the liver enzyme CYP1A2, which raises blood levels of caffeine, theophylline, and several other common drugs. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Selective serotonin reuptake inhibitor with high-affinity sigma-1 receptor agonism

    A 2-aminoethyl oxime ether SSRI developed at Kali-Duphar as an antidepressant and anti-obsessional agent, distinguished from other serotonin reuptake inhibitors by potent sigma-1 receptor agonism and downstream anti-inflammatory, cytoprotective, and endoplasmic reticulum chaperone activity.

    Abstract

    Fluvoxamine, the (E)-5-methoxy-1-[4-(trifluoromethyl)phenyl]pentan-1-one O-(2-aminoethyl)oxime, is a selective serotonin reuptake inhibitor (SSRI) of the 2-aminoethyl oxime ether structural class, first introduced in Switzerland in 1983 as Floxyfral and approved by the United States Food and Drug Administration in December 1994 for the treatment of obsessive-compulsive disorder (OCD). It is marketed in approximately 80 countries under the trade names Luvox, Fevarin, Faverin, Floxyfral, and Dumyrox for indications including OCD, social anxiety disorder (SAD), and major depressive disorder (MDD), with the extended-release formulation (Luvox CR) approved in the United States in 2008 for both OCD and SAD. Fluvoxamine is pharmacologically distinguished from the other marketed SSRIs (fluoxetine, sertraline, paroxetine, citalopram, escitalopram) by its potent agonism at the sigma-1 receptor, a ligand-regulated endoplasmic reticulum chaperone protein, with a binding affinity (Ki approximately 36 nM) that is the highest of any clinically used SSRI and approximately 10-fold greater than that of sertraline, the next most potent sigma-1 ligand in the class [1, 2]. The sigma-1 receptor activity, formally characterized by Narita et al. (1996) and subsequently extended by multiple laboratory groups in rodent models and by Hashimoto and colleagues in translational studies, drives a pharmacological profile that extends substantially beyond serotonin reuptake inhibition: activation of the sigma-1 receptor chaperone at the mitochondria-associated endoplasmic reticulum membrane (MAM) modulates the inositol 1,4,5-trisphosphate receptor (IP3R), stabilizes the IRE1-BiP complex under endoplasmic reticulum stress, suppresses NLRP3 inflammasome and NF-kappaB-driven proinflammatory cytokine release, and potentiates nerve growth factor-induced neurite outgrowth in neuronal cell models [3, 4, 5]. These properties have positioned fluvoxamine as a candidate for drug repositioning in inflammatory and infectious disease, most notably in the SARS-CoV-2 pandemic, where the TOGETHER trial (Reis et al. 2022) demonstrated a 32 percent relative risk reduction in the composite endpoint of emergency department retention or hospitalization among high-risk COVID-19 outpatients treated with fluvoxamine 100 mg twice daily for 10 days compared to placebo [6]. Pharmacokinetics in humans are characterized by near-complete gastrointestinal absorption, approximately 53 percent oral bioavailability due to first-pass hepatic metabolism, a plasma elimination half-life of 12 to 15 hours after single doses (extended at steady state owing to nonlinear pharmacokinetics from autoinhibition of CYP1A2 and CYP2C19), and oxidative demethylation through CYP2D6 and CYP1A2 followed by glucuronide conjugation and renal excretion [7, 8]. Fluvoxamine is itself a potent inhibitor of CYP1A2 and CYP2C19 and a moderate inhibitor of CYP3A4 and CYP2C9, producing clinically significant drug-drug interactions with theophylline, tizanidine, alosetron, clozapine, warfarin, and ramelteon, among others [9]. The compound is well tolerated at registered doses; the principal adverse events are nausea (up to 40 percent), somnolence, insomnia, headache, and asthenia, with serotonin syndrome as a rare but serious risk in combination with other serotonergic agents or monoamine oxidase inhibitors. This monograph reviews the chemistry, synthesis, and structural class of fluvoxamine; the dual SSRI and sigma-1 receptor pharmacology in molecular and translational detail; the comprehensive human pharmacokinetic record; the clinical evidence base across OCD, SAD, MDD, COVID-19, and investigational anti-inflammatory indications; sourcing and quality verification considerations; reconstitution and handling; stack-interaction considerations; adverse-event signal; and a comparative assessment of five serotonergic or sigma-1-active compounds against fluvoxamine on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1465Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Acarbose

    Plain-language summaryIntrigue 70 / 100

    Acarbose (Precose) is an alpha-glucosidase inhibitor isolated from a soil bacterium and approved in 1996 for type 2 diabetes. It blocks intestinal enzymes that break down complex carbohydrates, slowing carbohydrate absorption and flattening post-meal glucose spikes. Clinically it is a second-tier diabetes drug owing to gastrointestinal side effects (gas, bloating) from undigested carbohydrate fermenting in the colon. The longevity interest comes from the NIA Interventions Testing Program, which reproducibly showed that acarbose extends mouse lifespan, particularly in males, with effects that hold across different diets and genetic backgrounds. The replication is unusually solid for a longevity compound, even if the mouse-to-human translation is uncertain. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Pseudotetrasaccharide alpha-glucosidase inhibitor with pancreatic alpha-amylase inhibitory activity

    A microbially derived pseudotetrasaccharide developed at Bayer AG as a competitive intestinal alpha-glucosidase and pancreatic alpha-amylase inhibitor for postprandial glucose control in type 2 diabetes mellitus, with emerging preclinical evidence for lifespan extension, gut microbiome modulation, and cardiovascular risk reduction.

    Abstract

    Acarbose is a pseudotetrasaccharide alpha-glucosidase inhibitor isolated from fermentation cultures of the actinobacterium Actinoplanes utahensis and subsequently produced at industrial scale by Actinoplanes sp. SE50/110. The compound competitively and reversibly inhibits the brush border alpha-glucosidases (maltase-glucoamylase, sucrase-isomaltase) of the small intestinal epithelium and, at higher concentrations, pancreatic alpha-amylase, thereby delaying the hydrolysis of complex carbohydrates and oligosaccharides to absorbable monosaccharides and producing a dose-dependent reduction in postprandial glycemic excursion without direct stimulation of insulin secretion [1, 2]. Acarbose received its first regulatory approval in Germany in 1990 and was approved by the United States Food and Drug Administration in 1995 under the trade name Precose; it is marketed in over 100 countries worldwide as Glucobay (Bayer) and under multiple generic names. The compound is one of the most widely prescribed antidiabetic agents in East Asia, where postprandial hyperglycemia contributes disproportionately to overall glycemic burden in carbohydrate-rich dietary patterns. The pharmacokinetic profile of acarbose is dominated by its topical mechanism of action within the gastrointestinal lumen. Less than 2 percent of an oral dose is absorbed as intact drug; the remainder is degraded by intestinal bacteria and digestive enzymes in the distal small intestine and colon, producing at least 13 metabolites, of which one (4-methylpyrogallol and its conjugates) accounts for the majority of systemically absorbed radioactivity [3, 4]. Systemic exposure is therefore minimal, and the pharmacodynamic effect is determined by intraluminal drug concentration relative to the enzyme targets rather than by plasma pharmacokinetics. The compound is not metabolized by hepatic cytochrome P450 enzymes and has negligible renal clearance of intact drug. Clinical evidence for acarbose in type 2 diabetes mellitus is extensive. Pivotal registration trials demonstrated reductions in glycated hemoglobin (HbA1c) of 0.5 to 0.8 percentage points and reductions in postprandial glucose of 40 to 60 mg/dL at oral doses of 50 to 100 mg three times daily with meals [5, 6]. The UKPDS 44 substudy confirmed sustained glycemic efficacy over 3 years as add-on therapy to sulfonylurea or metformin [7]. The STOP-NIDDM trial (Study to Prevent Non-Insulin-Dependent Diabetes Mellitus) in 1368 subjects with impaired glucose tolerance demonstrated a 25 percent relative risk reduction in progression to type 2 diabetes and a 49 percent relative risk reduction in cardiovascular events over 3.3 years of treatment, though the cardiovascular endpoint was secondary and based on a small number of events [8, 9]. The larger ACE trial (Acarbose Cardiovascular Evaluation) in 6522 Chinese patients with coronary heart disease and impaired glucose tolerance found no reduction in major adverse cardiovascular events over 5 years of follow-up but confirmed an 18 percent relative risk reduction in incident diabetes [10]. Beyond the established antidiabetic indication, acarbose has attracted substantial recent interest as a longevity intervention. The National Institute on Aging Interventions Testing Program (ITP), a rigorous, multi-site, genetically heterogeneous mouse study, demonstrated that acarbose at 1000 ppm in chow extended median lifespan by approximately 22 percent in males and 5 percent in females, with corresponding increases in maximum lifespan [11, 12]. The sex-differential effect parallels the male-preferential lifespan extension observed with 17-alpha-estradiol and nordihydroguaiaretic acid in the same program. Mechanistic investigations have linked the longevity effect to increased delivery of undigested starch to the colonic microbiome, resulting in elevated production of short-chain fatty acids (butyrate, propionate, acetate), shifts in microbial community composition toward Bacteroidetes-dominant profiles, and reductions in circulating insulin-like growth factor 1 (IGF-1) and fasting insulin [13, 14]. Combination of acarbose with rapamycin in the ITP produced additive lifespan extension (median lifespan increases of 28 percent in females and 34 percent in males when initiated at 9 months of age), supporting the hypothesis that the two compounds operate through complementary pathways [15]. The principal adverse effects of acarbose are gastrointestinal: flatulence (reported in up to 78 percent of patients at initiation), diarrhea, and abdominal discomfort, all reflecting the mechanism of action (bacterial fermentation of undigested carbohydrate in the colon) and typically diminishing with continued therapy and gradual dose titration [16]. Rare hepatotoxicity, presenting as asymptomatic transaminase elevation or, in isolated cases, clinically apparent hepatocellular injury, has been reported in postmarketing surveillance and is generally reversible upon discontinuation [17]. This monograph reviews the chemistry, biosynthesis, and structural pharmacology of acarbose; the mechanism of alpha-glucosidase and alpha-amylase inhibition at the molecular level; the comprehensive pharmacokinetic record; the clinical evidence base across antidiabetic, diabetes prevention, cardiovascular, and longevity indications; sourcing and quality verification considerations; reconstitution and handling; stack-interaction implications; adverse-event signal; and a comparative assessment of five alternative glucose-lowering or longevity-relevant compounds against acarbose on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1476Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • CP2

    Tricyclic pyrone mild mitochondrial complex I inhibitor with direct amyloid-beta binding activity

    A cell-permeable tricyclic pyranopyrone synthesized at Kansas State University as an anti-amyloidogenic agent, subsequently characterized as a mild inhibitor of mitochondrial complex I that activates AMPK-dependent neuroprotective signaling, crosses the blood-brain barrier, and reduces amyloid-beta, phosphorylated tau, oxidative stress, and neuroinflammation in multiple transgenic mouse models of familial Alzheimer’s disease.

    Abstract

    CP2 is a synthetic tricyclic pyrone (pyranopyrone) small molecule originally developed as part of a structure-activity exploration of anti-amyloidogenic agents in the laboratory of Duy H. Hua at Kansas State University and first reported in the biomedical literature as a cell-permeable inhibitor of amyloid-beta oligomeric complex formation in the MC65 neuroblastoma conditional expression system by Maezawa et al. (2006) [1]. The compound consists of a fused tricyclic pyranopyrone skeleton bearing an adenine moiety attached through its N3′ nitrogen to the C7 isopropyl substituent of the cyclohexane ring. CP2 exists as two diastereomers, designated D1 and D2, with distinct pharmacological activity and toxicity profiles that have been resolved by X-ray crystallography and cryo-electron microscopy at 3.25 to 3.27 angstrom resolution [2]. The D1 diastereomer is the more pharmacologically active form. The compound was initially characterized as a direct binder of amyloid-beta peptides, with exceptionally high binding affinity to amyloid-beta 40 (Kd approximately 5.05 nanomolar) and high affinity to amyloid-beta 42 (Kd approximately 269 nanomolar), and as an inhibitor of amyloid-beta oligomerization and fibril formation in surface plasmon resonance and atomic force microscopy assays [3, 4]. Subsequent mechanistic investigation by Zhang et al. (2015) identified the primary intracellular target as mitochondrial complex I (NADH:ubiquinone oxidoreductase), the first and largest enzyme complex of the electron transport chain [5]. Molecular dynamics simulations and cryo-electron microscopy demonstrated that the cationic CP2 molecule competes with flavin mononucleotide for binding to the redox subunit of human mitochondrial complex I, leading to mild (partial) inhibition of complex I activity, elevated AMP-to-ATP ratio, and consequent activation of AMP-activated protein kinase (AMPK) in neurons and in mouse brain without inducing oxidative damage or inflammation [5, 6]. In vivo, CP2 is orally bioavailable, penetrates the blood-brain barrier, and accumulates in neuronal mitochondria. Chronic oral administration at 25 mg/kg/day in drinking water in multiple transgenic mouse models of familial Alzheimer’s disease (Tg2576, 3xTg-AD, APP/PS1, 5xFAD) has produced consistent reductions in amyloid-beta and phosphorylated tau accumulation, oxidative stress, neuroinflammation, and cognitive dysfunction, while improving mitochondrial function, energy homeostasis, synaptic activity, dendritic spine density and morphology, and long-term potentiation in the hippocampus [5, 7, 8, 9]. The compound also prevents aggregation and reverses cellular phenotypes caused by expression of mutant huntingtin protein in striatal neurons, extending the potential disease relevance beyond Alzheimer’s disease to Huntington’s disease [10]. A 2025 study by Gao et al. demonstrated that mitochondrial complex I deficiency alone induces Alzheimer’s disease-like transcriptomic signatures in the brain, and that these signatures are partially reversible by CP2 treatment, providing further mechanistic support for the therapeutic strategy [11]. CP2 has not entered human clinical trials. The compound remains a preclinical research tool and investigational candidate. Structure-activity relationship studies have produced a next-generation analog, C458 (cis-(N-(pyridin-4-ylmethyl)-2-(3-(m-tolyloxy)cyclohexyl)propan-1-amine)), with improved drug-like properties, favorable pharmacokinetics, minimal off-target effects, and excellent brain penetrance [2, 12]. This monograph reviews the chemistry, synthesis, and stereochemistry of CP2; the dual mechanism of action encompassing direct amyloid-beta binding and mild mitochondrial complex I inhibition; the pharmacokinetic profile in rodents; the preclinical evidence base across Alzheimer’s disease and Huntington’s disease models; sourcing and handling considerations for laboratory use; stack interaction considerations; the adverse event and safety signal from preclinical data; and a comparative assessment of five mitochondrial-targeted or anti-amyloidogenic neuroprotective candidates against CP2 on five competency standards (novelty, effect size, promising potential, side-effect profile, and overall validation). The compound is not approved by any regulatory agency and is not registered as a medicine in any jurisdiction. It is supplied as a research-grade preparation; investigators should obtain analytical confirmation of identity and purity on every lot.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1471Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Withaferin-A

    Steroidal lactone withanolide with multi-target anticancer, anti-inflammatory, and metabolic activity

    A C28-ergostane-type steroidal lactone isolated from Withania somnifera, distinguished by covalent multi-target pharmacology spanning NF-kappaB inhibition, vimentin intermediate filament disruption, Hsp90 C-terminal binding, and leptin sensitization, with preclinical anticancer efficacy across multiple tumor types and an emerging Phase I clinical safety record in advanced osteosarcoma.

    Abstract

    Withaferin-A (WA), the prototypical withanolide and the first member of the C28-ergostane steroidal lactone class to be structurally characterized, is a naturally occurring phytochemical isolated principally from the leaves and roots of Withania somnifera (Linnaeus) Dunal (Solanaceae), a plant used for millennia in Ayurvedic medicine under the common name ashwagandha. The compound was first isolated by Lavie and colleagues in 1965 from the leaves of Withania somnifera and Acnistus arborescens, and its structural elucidation established the withanolide class as a distinct group of naturally occurring steroidal lactones characterized by a C28-ergostane skeleton with an oxidized delta-lactone side chain formed between carbons 22 and 26 [1, 2]. The chemical reactivity of Withaferin-A derives from three electrophilic pharmacophores: the alpha,beta-unsaturated ketone in the A ring, the 5beta,6beta-epoxide in the B ring, and the unsaturated delta-lactone in the side chain, each capable of forming covalent adducts with nucleophilic cysteine residues on target proteins through Michael addition chemistry [3].

    The molecular pharmacology of Withaferin-A is characterized by covalent, multi-target engagement. The compound binds covalently to the sole cysteine residue (Cys328 in human vimentin) in the alpha-helical coiled-coil 2B domain of the intermediate filament protein vimentin, inducing filament aggregation, disrupting cytoskeletal architecture, and inhibiting epithelial-to-mesenchymal transition in cancer cells [4, 5]. It inhibits NF-kappaB signaling by direct thioalkylation of IKKbeta, preventing IkappaB phosphorylation and nuclear translocation of the NF-kappaB p65/p50 heterodimer [6, 7]. It binds the C-terminal domain of Hsp90 through an ATP-independent mechanism, inducing proteasomal degradation of Hsp90 client proteins including Akt, Cdk4, and the glucocorticoid receptor [8]. Additional validated direct targets include annexin II, beta-tubulin, mortalin (mitochondrial Hsp70), KEAP1, and Bruton tyrosine kinase [3, 9]. The breadth of covalent target engagement produces convergent antiproliferative, pro-apoptotic, anti-angiogenic, and anti-inflammatory activity across multiple cancer cell lines and xenograft models.

    Preclinical anticancer efficacy has been demonstrated in xenograft and orthotopic tumor models of breast cancer (including triple-negative breast cancer), ovarian cancer, cervical carcinoma, glioblastoma, pancreatic cancer, melanoma, neuroblastoma, and multiple myeloma, with tumor growth inhibition typically observed at intraperitoneal doses of 2 to 8 mg/kg in mice [10, 11, 12]. Beyond oncology, Withaferin-A has been characterized as a leptin sensitizer with strong antidiabetic and anti-obesity properties; treatment of diet-induced obese mice produced 20 to 25 percent reduction in body weight, reversal of hepatic steatosis, and normalization of glucose metabolism independently of the leptin-sensitizing effect [13]. Neuroprotective activity has been demonstrated in multiple rodent models.

    Pharmacokinetics in rodents are characterized by low oral bioavailability (approximately 1.8 to 32 percent depending on formulation and species), rapid hepatic metabolism, and a short plasma half-life of approximately 1.36 hours in mice [14, 15]. The compound crosses the blood-brain barrier. The LD50 following oral administration in mice exceeds 2000 mg/kg body weight, placing Withaferin-A in GHS toxicity category 5 [16]. A Phase I dose-escalation clinical trial in patients with advanced-stage high-grade osteosarcoma (Pires et al. 2019) evaluated oral doses of 72, 108, 144, and 216 mg of Withaferin-A per day and reported tolerability without dose-limiting toxicity; adverse events were limited to grade 1 and grade 2 severity, principally liver enzyme elevation and skin rash [17]. The maximum tolerated dose was not reached. Circulating Withaferin-A could not be quantified by the HPLC bioanalytical method employed, consistent with the low oral bioavailability observed in preclinical studies and representing a principal translational challenge. This monograph reviews the chemistry, isolation, and biosynthesis of Withaferin-A; the covalent multi-target pharmacology; the pharmacokinetic record; the preclinical efficacy across oncology, metabolic, and neurological models; the Phase I clinical evidence; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse-event signal; and a comparative assessment of five natural-product anticancer and anti-inflammatory candidates against Withaferin-A on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1483Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • MitoTEMPO

    Mitochondria-targeted nitroxide antioxidant and superoxide dismutase mimetic

    A triphenylphosphonium-conjugated piperidine nitroxide developed as a mitochondria-selective superoxide scavenger, distinguished from conventional antioxidants by its several-hundred-fold accumulation in energized mitochondria and its established preclinical efficacy across cardiovascular, renal, hepatic, and neurological models of oxidative injury.

    Abstract

    MitoTEMPO (2-(2,2,6,6-tetramethylpiperidin-1-oxyl-4-ylamino)-2-oxoethyl)triphenylphosphonium chloride) is a mitochondria-targeted superoxide dismutase (SOD) mimetic that combines the piperidine nitroxide TEMPO radical with a lipophilic triphenylphosphonium (TPP+) cation. The TPP+ moiety exploits the large negative-inside mitochondrial membrane potential (approximately 150 to 180 mV) to drive electrophoretic accumulation of the compound across the inner mitochondrial membrane, achieving intramitochondrial concentrations several hundred-fold greater than extracellular concentrations in energized cells [1, 2]. Once localized to the mitochondrial matrix, the nitroxide radical undergoes a catalytic cycle between its oxidized (nitroxide) and reduced (hydroxylamine) forms, dismuting superoxide to hydrogen peroxide and molecular oxygen in a reaction that functionally mimics manganese superoxide dismutase (MnSOD, SOD2) [3]. This SOD-mimetic activity is complemented by alkyl radical scavenging capacity, enabling MitoTEMPO to interrupt lipid peroxidation chain reactions within the mitochondrial inner membrane. The compound was first characterized in a cardiovascular context by Dikalova, Dikalov, and colleagues at Emory University in a 2010 Circulation Research report demonstrating that MitoTEMPO attenuated angiotensin II-induced hypertension in mice at doses 1000-fold lower than the non-targeted parent compound TEMPOL, reduced mitochondrial and total cellular superoxide, restored vascular nitric oxide bioavailability, and improved endothelial-dependent relaxation [1]. This seminal study established MitoTEMPO as a pharmacological tool for dissecting the contribution of mitochondrial reactive oxygen species (mtROS) to disease pathogenesis and stimulated a broad preclinical literature now spanning hypertension, heart failure, ischemia-reperfusion injury, doxorubicin cardiotoxicity, diabetic nephropathy, acetaminophen hepatotoxicity, hepatocarcinogenesis, sepsis-associated acute kidney injury, noise-induced hearing loss, radiation injury, neurodegenerative disease models, and chronic pain. MitoTEMPO has not entered human clinical trials. No regulatory authority has approved it for therapeutic use. The compound remains a research-grade tool, supplied by multiple chemical vendors (Sigma-Aldrich, Cayman Chemical, Selleckchem, MedChemExpress, others) at greater than 98 percent purity by HPLC. Its physicochemical profile is favorable for in vitro and in vivo research: molecular weight 510.03 g/mol (chloride salt), freely soluble in water and dimethyl sulfoxide, stable as a dry powder at minus 20 degrees Celsius for at least three years, and amenable to intraperitoneal, intravenous, and subcutaneous administration in rodent models at doses typically ranging from 0.7 to 10 mg/kg/day. Formal pharmacokinetic studies characterizing oral bioavailability, plasma half-life, and metabolic disposition in any species have not been published; the preclinical literature relies on functional endpoints (superoxide reduction, blood pressure attenuation, organ protection) rather than on classical pharmacokinetic parameters. This monograph reviews the chemistry, synthesis, and structural class of MitoTEMPO; the SOD-mimetic and radical-scavenging mechanism in molecular detail; the available pharmacokinetic and biodistribution data; the preclinical pharmacology across cardiovascular, renal, hepatic, neurological, and inflammatory models; the absence of clinical evidence; sourcing and quality verification; reconstitution and handling; stack interactions with other mitochondria-targeted agents and redox-active compounds; adverse events and safety signals from animal studies; and a comparative assessment of five mitochondria-targeted antioxidant candidates (MitoQ, elamipretide/SS-31, SkQ1, MitoVitE, TEMPOL) against MitoTEMPO on five competency standards (novelty, effect size, promising potential, side-effect profile, and overall validation).

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1469Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • R-13

    Flavonoid-derived carbamate prodrug of 7,8-dihydroxyflavone with selective tropomyosin receptor kinase B agonist activity

    A rationally designed bis-carbamate prodrug of 7,8-dihydroxyflavone engineered for improved oral bioavailability and sustained brain-derived neurotrophic factor receptor activation, advancing through Phase 1 clinical evaluation for Alzheimer’s disease and under preclinical investigation for amyotrophic lateral sclerosis, depression, Parkinson’s disease, and peripheral nerve regeneration.

    Abstract

    R-13 (BrAD-R13, Braegen-01) is a synthetic bis-methylcarbamate prodrug of 7,8-dihydroxyflavone (7,8-DHF; tropoflavin), designed to overcome the poor oral bioavailability and rapid hepatic conjugation of the parent flavone while preserving its selective agonist activity at the tropomyosin receptor kinase B (TrkB) receptor, the principal high-affinity signaling receptor for brain-derived neurotrophic factor (BDNF). The compound was identified through systematic medicinal chemistry optimization of ester and carbamate modifications on the 7,8-DHF catechol ring by Chen, Ye, and colleagues at Emory University School of Medicine and Zhejiang University, with R-13 selected from among twenty candidate derivatives as the sole compound satisfying all screening criteria for gastric acid stability, intestinal absorption, hydrolyzability in liver microsomes and plasma, and adequate membrane permeability. Following oral administration, R-13 is hydrolyzed through a monophenol intermediate (designated T1) to release 7,8-DHF, which binds the extracellular domain of TrkB and triggers receptor dimerization, autophosphorylation, and activation of the downstream Akt and ERK/MAPK signaling cascades. In mice, R-13 at 36 mg/kg oral dose produces a maximum plasma concentration of 129 ng/mL at 30 minutes, with an elimination half-life of approximately 220 minutes and oral bioavailability of 10.5 percent (compared to 4.6 percent for the parent 7,8-DHF), and sustains brain 7,8-DHF concentrations above 8 ng/g for at least 4 hours. The pharmacological consequences of sustained TrkB activation are broad: R-13 represses asparagine endopeptidase (AEP, also termed delta-secretase), a protease implicated in the pathological cleavage of both amyloid precursor protein and tau in Alzheimer’s disease, thereby reducing amyloid-beta deposition and neurofibrillary tangle formation. Chronic oral administration of R-13 in the 5XFAD transgenic mouse model of Alzheimer’s disease dose-dependently restored dendritic spine density, enhanced long-term potentiation, reduced senile plaque burden, attenuated neuroinflammatory cytokine levels (interleukin-1-beta, interleukin-6, tumor necrosis factor alpha), and reversed spatial and working memory deficits in the Morris water maze without demonstrable toxicity at 12 weeks of continuous dosing at up to 43.6 mg/kg/day. Additional preclinical evidence supports efficacy in the SOD1-G93A transgenic mouse model of amyotrophic lateral sclerosis, where R-13 preserved motor neuron counts, reduced gastrocnemius muscle atrophy, attenuated glial activation, and enhanced mitochondrial biogenesis through AMPK/PGC-1-alpha/Nrf1/Tfam pathway activation. In a peripheral nerve transection model, oral R-13 produced axon regeneration and functional electromyographic recovery superior to the parent 7,8-DHF. R-13 has also been characterized as preventing ovariectomy-induced bone loss through TrkB/Akt-mediated inhibition of AEP and upregulation of osteoprotegerin. Braegen Pharmaceutical (Shenzhen, China) has completed a Phase 1 clinical trial of BrAD-R13 in Alzheimer’s disease, the first clinical evaluation of a TrkB agonist prodrug in this indication, with plans for Phase 2 efficacy trials. The compound is not approved in any jurisdiction for any indication. This monograph reviews the chemistry, synthesis, and prodrug design of R-13; the TrkB receptor pharmacology and downstream signaling; the comprehensive preclinical pharmacokinetic profile; the evidence base across Alzheimer’s disease, amyotrophic lateral sclerosis, peripheral nerve injury, bone metabolism, and neuropsychiatric indications; sourcing and handling for research applications; stack-interaction considerations; adverse-event signal; and a comparative assessment of five alternative TrkB agonist and BDNF-mimetic candidates against R-13 on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1489Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Xanomeline-Trospium

    Fixed-dose combination of an M1/M4-preferring muscarinic acetylcholine receptor agonist and a peripherally restricted non-selective muscarinic antagonist

    A first-in-class muscarinic agonist combination pairing the centrally acting M1/M4-preferring agonist xanomeline with the peripherally restricted muscarinic antagonist trospium chloride, approved by the United States Food and Drug Administration in September 2024 for the treatment of schizophrenia in adults, representing the first non-dopamine-D2-blocking antipsychotic mechanism registered for psychotic illness.

    Abstract

    Xanomeline-trospium (KarXT; marketed as Cobenfy) is a fixed-dose oral combination of xanomeline tartrate, a functionally selective muscarinic acetylcholine receptor agonist with preferential activity at the M1 and M4 receptor subtypes, and trospium chloride, a quaternary ammonium muscarinic antagonist that does not appreciably cross the blood-brain barrier. The combination was designed to preserve the central antipsychotic and procognitive effects of muscarinic M1/M4 agonism while mitigating the dose-limiting peripheral cholinergic adverse events (nausea, vomiting, diarrhea, hypersalivation, diaphoresis) that had previously terminated the clinical development of xanomeline as a monotherapy agent. The United States Food and Drug Administration approved xanomeline-trospium on 26 September 2024 for the treatment of schizophrenia in adults, making it the first antipsychotic mechanism approved since the introduction of the dopamine D2 receptor antagonist and partial agonist classes and the first muscarinic-based treatment registered for any psychotic disorder.

    Xanomeline was originally synthesized in a collaboration between Eli Lilly and Novo Nordisk in the early 1990s under the development code LY-246708. Initial clinical development targeted Alzheimer’s disease, where a 343-patient Phase 2 trial (Bodick et al. 1997) demonstrated stabilization of cognitive decline and significant dose-dependent reductions in behavioral and psychological symptoms including hallucinations, delusions, agitation, and vocal outbursts. However, peripheral cholinergic adverse events led to unacceptable dropout rates and the Alzheimer’s program was discontinued. A subsequent proof-of-concept trial in schizophrenia (Shekhar et al. 2008) confirmed antipsychotic-like activity through a non-dopaminergic mechanism but was similarly limited by tolerability. The critical innovation was the combination with trospium chloride, a muscarinic antagonist previously approved for overactive bladder (Sanctura, Allergan) that is restricted to the peripheral compartment by its quaternary ammonium structure and does not undergo cytochrome P450 metabolism. This combination strategy was advanced by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb for approximately 14 billion United States dollars in 2024.

    The registration of xanomeline-trospium was supported by three randomized, double-blind, placebo-controlled, 5-week Phase 3 trials (EMERGENT-1, EMERGENT-2, EMERGENT-3) in adults with schizophrenia experiencing acute psychosis. In pooled analyses across all three trials, xanomeline-trospium produced a statistically significant reduction in Positive and Negative Syndrome Scale (PANSS) total score compared to placebo (least squares mean difference, minus 9.9 points; 95 percent confidence interval, minus 12.4 to minus 7.3; p less than 0.0001; Cohen’s d effect size, 0.65). Effects were observed across positive symptom, negative symptom, and general psychopathology PANSS subscales and on the Clinical Global Impression-Severity scale. Long-term safety and efficacy were characterized in the 52-week open-label extension trials EMERGENT-4 and EMERGENT-5, which demonstrated sustained symptom improvement, a mean change in body weight of minus 1.9 kilograms from acute trial baseline, no clinically meaningful changes in prolactin levels, and no treatment-emergent akathisia or tardive dyskinesia. The most common adverse events were gastrointestinal (nausea, dyspepsia, constipation, vomiting) and were generally mild to moderate, transient, and manageable without treatment discontinuation in most patients.

    The compound is currently in Phase 3 development for additional indications including psychosis associated with Alzheimer’s disease (ADEPT program), agitation associated with Alzheimer’s disease (ADAGIO program), and cognitive impairment in Alzheimer’s disease. An enteric-coated xanomeline formulation (KarX-EC) is in development with the aim of further reducing gastrointestinal adverse events. This monograph reviews the chemistry, synthesis, and pharmacology of both components; the composite mechanism of action through central muscarinic M1/M4 agonism with peripheral muscarinic blockade; the pharmacokinetics including CYP2D6 polymorphism effects; the complete clinical evidence base across schizophrenia and Alzheimer’s disease indications; sourcing and quality considerations; reconstitution and handling; stack-interaction implications; adverse-event and safety signal; and a comparative assessment of five alternative antipsychotic or muscarinic-targeted agents against xanomeline-trospium on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1457Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.